Srinivas Veerla

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Breast Cancer Risk

Genome Wide Association

Top Venues

NPJ breast cancer

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Srinivas Veerla, Johan Staaf
Kataegis in clinical and molecular subgroups of primary breast cancer. NPJ breast cancer 10 (1) (2024)
Srinivas Veerla, Johan Staaf
Kataegis in clinical and molecular subgroups of primary breast cancer. NPJ breast cancer 10 (1) (2024)
Praveen Papareddy, Ines Tapken, Keshia Kroh, Ravi Kiran Varma Bhongir, Milladur Rahman, Maria Baumgarten, Eda Irem Cim, Lilla Györffy, Emanuel Smeds, Ariane Neumann, Srinivas Veerla, Jon Olinder, Henrik Thorlacus, Cecilia Ryden, Eva Bartakova, Michal Holub, Heiko Herwald
The role of extracellular vesicle fusion with target cells in triggering systemic inflammation. Nature communications 15 (1) (2024)
Srinivas Veerla, Johan Staaf
Kataegis in clinical and molecular subgroups of primary breast cancer. NPJ breast cancer 10 (1) (2024)
Praveen Papareddy, Ines Tapken, Keshia Kroh, Ravi Kiran Varma Bhongir, Milladur Rahman, Maria Baumgarten, Eda Irem Cim, Lilla Györffy, Emanuel Smeds, Ariane Neumann, Srinivas Veerla, Jon Olinder, Henrik Thorlacus, Cecilia Ryden, Eva Bartakova, Michal Holub, Heiko Herwald
The role of extracellular vesicle fusion with target cells in triggering systemic inflammation. Nature communications 15 (1) (2024)
Praveen Papareddy, Ines Tapken, Keshia Kroh, Ravi Kiran Varma Bhongir, Milladur Rahman, Maria Baumgarten, Eda Irem Cim, Lilla Györffy, Emanuel Smeds, Ariane Neumann, Srinivas Veerla, Jon Olinder, Henrik Thorlacus, Cecilia Ryden, Eva Bartakova, Michal Holub, Heiko Herwald
The role of extracellular vesicle fusion with target cells in triggering systemic inflammation. Nature communications 15 (1) (2024)
Srinivas Veerla, Lennart Hohmann, Deborah F Nacer, Johan Vallon-Christersson, Johan Staaf
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer. NPJ breast cancer 9 (1) (2023)